The FDA hosted a virtual workshop January 26, 2021 to provide updates and foster discussions around non-clinical assays for comparative immunogenicity risk assessment of generic peptide products.

EpiVax CEO/CSO, Annie De Groot, presented an update on EpiVax’s PANDA (Peptide Abbreviated New Drug Application) immunogenicity assessment. Her talk features research updates on two case studies, work carried out as part of an ongoing FDA contract to provide validation of new immunoinformatic tools for prospective immunogenicity assessment of peptide drugs and their impurities.  

The complete event recording can be found here on the FDA website.

View Annie’s segment below!